Development and validation of a simple and rapid way to generate low volume of plasma to be used in point-of-care HIV virus load technologies
Isabelle Vasconcellos, Diana Mariani, Marcelo C V M de Azevedo, Orlando C Ferreira Jr, Amilcar Tanuri, Isabelle Vasconcellos, Diana Mariani, Marcelo C V M de Azevedo, Orlando C Ferreira Jr, Amilcar Tanuri
Abstract
A new point-of-care HIV viral load, mPIMA HIV-1/2 VL, Abbott, USA, has been recently developed. This point-of-care viral load requires no skilled person to run and uses a small plasma volume (50μL). However, obtaining 50μL of plasma can be a challenge in limited resource settings. We validated a simple and easy method to obtain enough amount of plasma to run a point-of-care viral load. The study utilized 149 specimens from patients failing antiretroviral therapy. At least 250μL of whole blood was collected in a microtube/EDTA from fingerstick (fs-plasma) and immediately centrifuged. Parallel collection of venous blood to obtain plasma (vp-plasma) was used to compare performance in a point-of-care viral load assay and in methodology used in centralized laboratories Abbott M2000, Abbott, USA. The procedure for plasma collection takes less than 10min and in 94% of the cases only one fingerstick was sufficient to collect at least 250μL of blood. The Pearson correlation coefficient value for vp-plasma versus fs-plasma ran on mPIMA was 0.990. The Bland-Altman mean difference (md) for this comparison were virtually zero (md=-0.001) with limits of agreement between -0.225 and 0.223. In addition, the Pearson correlation coefficient value for fs-plasma in mPIMA versus vp-plasma in Abbott M2000 was 0.948 for values above the mPIMA limit of quantification (LoQ; from 800 to 1,000,000copies/mL). These results validate this simple plasma isolation method capable to be implemented in low resource countries where point-of-care decentralization is deeply needed.
Keywords: Fingerstick-plasma; HIV; HIV viral load; POC VL; Point-of-care; mPIMA.
Copyright © 2019 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. All rights reserved.
Figures
References
- World Health Organization . 2015. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: ecommendations for a public health approach.
- UNAIDS . 2014. 90–90–90 an ambitious treatment target to help end the AIDS epidemic.
- UNAIDS . 2014. Landmark HIV diagnostic access program will save $150m and help achieve new global goals on HIV.
- Saito S., Duong Y.T., Metz M., et al. Returning HIV-1 viral load results to participant-selected health facilities in national population-based HIV impact assessment (PHIA) household surveys in three sub-Saharan African Countries, 2015 to 2016. J Int AIDS Soc. 2017;20(Suppl. 7):19–25.
- Frank S.C., Cohn J., Dunning L., et al. Clinical effect and cost-effectiveness of incorporation of point-of-care assays into early infant HIV diagnosis programmes in Zimbabwe: a modelling study. Lancet HIV. 2019;6:182–190.
- Ceffaa S., Luhangab R., Andreottic M., et al. Comparison of the Cepheid GeneXpert and Abbott M2000 HIV-1 realtime molecular assays for monitoring HIV-1 viral load and detectingHIV-1 infection. J Virol Methods. 2016;229:35–39.
- Zeh C., NdiegeK, Inzaule S., et al. Evaluation of the performance of Abbottm2000 and Roche COBASAmpliprep/COBAS Taqman assays for HIV-1 viral load determination using dried bloodspots and dried plasma spots in Kenya. PLoS ONE. 2017;12:e0179316. doi: 10.1371/journal.pone.0179316.
Source: PubMed